Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters

Journal of Neurochemistry

Volumn 98, Issue 5, 2006, Pages 1531-1540

  Mortensen, Ole V ^a   Amara, Susan G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Benztropine; Bupropion; Monoamine transporter; Site directed mutagenesis; Structure function study

Indexed keywords

ALANINE; AMFEBUTAMONE; AMINO ACID; BENZATROPINE; DOPAMINE TRANSPORTER; MONOAMINE; MUTANT PROTEIN; NISOXETINE; NORADRENALIN TRANSPORTER; SERINE; TRITIUM;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

ALANINE; ANIMALS; BENZTROPINE; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BUPROPION; CERCOPITHECUS AETHIOPS; COS CELLS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOXETINE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOLIGAND ASSAY; SERINE; TRANSFECTION; TRITIUM;

EID: 33746874860     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04060.x     Document Type: Article

References (42)

1. Acri J. B., Siedleck B. K. and Witkin J. M. (1996) Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1- [2-(diphenylmethoxy) ethyl]-4-(3-phenyl- propyl)-piperazine. J. Pharmacol. Exp. Ther. 277, 198-206.
2. Amara S. G. and Kuhar M. J. (1993) Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73-93., 73-93.
3. Barker E. L. and Blakely R. D. (1996) Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol. Pharmacol. 50, 957-965.
4. Barker E. L., Perlman M. A., Adkins E. M., Houlihan W. J., Pristupa Z. B., Niznik H. B. and Blakely R. D. (1998) High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J. Biol. Chem. 273, 19 459-19 468.
5. Barker E. L., Moore K. R., Rakhshan F. and Blakely R. D. (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19, 4705-4717.
6. Buck K. J. and Amara S. G. (1995) Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48, 1030-1037.
7. Chen J. G., Sachpatzidis A. and Rudnick G. (1997) The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 272, 28 321-28 327.
8. Chen N., Zhen J. and Reith M. E. (2004) Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J. Neurochem. 89, 853-864.
9. Danek B. K. and Justice J. B. J. (1999) Effects of serine mutations in transmembrane domain 7 of the human norepinephrine transporter on substrate binding and transport. J. Neurochem. 73, 656-664.
10. Dar D. E., Mayo C. and Uhl G. R. (2005) The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem. Pharmacol. 70, 461-469.
11. Desai R. I., Kopajtic T. A., Koffarnus M., Newman A. H. and Katz J. L. (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 25, 1889-1893.
12. Ferrer J. V. and Javitch J. A. (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc. Natl Acad. Sci. USA 95, 9238-9243.
13. Giros B., Wang Y. M., Suter S., McLeskey S. B., Pifl C. and Caron M. G. (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15 985-15 988.
14. Guex N. and Peitsch M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723.
15. Hahn M. K., Mazei-Robison M. S. and Blakely R. D. (2005) Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol. Pharmacol. 68, 457-466.
16. Halushka M. K., Fan J. B., Bentley K., Hsie L., Shen N., Weder A., Cooper R., Lipshutz R. and Chakravarti A. (1999) Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat. Genet. 22, 239-247.
17. Henry L. K., Field J. R., Adkins E. M., Parnas M. L., Vaughan R. A., Zou M. F., Newman A. H. and Blakely R. D. (2006) Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281, 2012-2023.
18. Iversen L. (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br. J. Pharmacol. 147, S82-S88.
19. Jayanthi L. D., Apparsundaram S., Malone M. D., Ward E., Miller D. M., Eppler M. and Blakely R. D. (1998) The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant and cocaine-sensitive dopamine transporter. Mol. Pharmacol. 54, 601-609.
20. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M. and Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785.
21. Kitayama S., Mitsuhata C., Davis S., Wang J. B., Sato T., Morita K., Uhl G. R. and Dohi T. (1998) MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wildtype and mutant rat dopamine transporters. Biochim. Biophys. Acta 1404, 305-313.
22. Kniazeff J., Loland C. J., Goldberg N., Quick M., Das S., Sitte H. H., Javitch J. A. and Gether U. (2005) Intramolecular cross-linking in a bacterial homolog of mammalian SLC6 neurotransmitter transporters suggests an evolutionary conserved role of transmembrane segments 7 and 8. Neuropharmacology 49, 715-723.
23. Larsen M. B., Elfving B. and Wiborg O. (2004) The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors. A species-scanning mutagenesis study. J. Biol. Chem. 279, 42 147-42 156.
24. Modell J. G., Tandon R. and Beresford T. P. (1989) Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J. Clin. Psychopharmacol. 9, 347-351.
25. Mortensen O. V., Kristensen A. S. and Wiborg O. (2001) Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J. Neurochem. 79, 237-247.
26. Newman A. H. and Kulkarni S. (2002) Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic - A focus on analogues of benztropine and rimcazole. Med. Res. Rev. 22, 429-464.
27. Paczkowski F. A. and Bryan-Lluka L. J. (2001) Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology. Brain Res. Mol. Brain Res. 97, 32-42.
28. Paczkowski F. A. and Bryan-Lluka L. J. (2002) Amino acids involved in differences in the pharmacological profiles of the rat and human noradrenaline transporters. Naunyn Schmiedeberg's Arch. Pharmacol. 365, 312-317.
29. Pedersen H., Sinning S., Bulow A., Wiborg O., Falborg L. and Bols M. (2004) Combinatorial synthesis of benztropine libraries and their evaluation as monoamine transporter inhibitors. Org. Biomol. Chem. 2, 2861-2869.
30. Porzgen P., Park S. K., Hirsh J., Sonders M. S. and Amara S. G. (2001) The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol. Pharmacol. 59, 83-95.
31. Reith M. E., Berfield J. L., Wang L. C., Ferrer J. V. and Javitch J. A. (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J. Biol. Chem. 276, 29 012-29 018.
32. Rothman R. B. (1990) High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci. 46, L17-L21.
33. Roubert C., Cox P. J., Bruss M., Hamon M., Bonisch H. and Giros B. (2001) Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J. Biol. Chem. 276, 8254-8260.
34. Sanchez C. and Hyttel J. (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. 19, 467-489.
35. Sucic S. and Bryan-Lluka L. J. (2005) Roles of transmembrane domain 2 and the first intracellular loop in human noradrenaline transporter function: pharmacological and SCAM analysis. J. Neurochem. 94, 1620-1630.
36. Sur C., Betz H. and Schloss P. (1997) A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc. Natl Acad. Sci. USA 94, 7639-7644.
37. Surratt C. K., Ukairo O. T. and Ramanujapuram S. (2005) Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters. AAPS J. 7, E739-E751.
38. Torres G. E., Gainetdinov R. R. and Caron M. G. (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4, 13-25.
39. Ukairo O. T., Bondi C. D., Newman A. H., Kulkarni S. S., Kozikowski A. P., Pan S. and Surratt C. K. (2005) Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J. Pharmacol. Exp. Ther. 314, 575-583.
40. Woolverton W. L., Rowlett J. K., Wilcox K. M., Paul I. A., Kline R. H., Newman A. H. and Katz J. L. (2000) 3′- and 4′-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys. Psychopharmacology 147, 426-435.
41. Wu X. and Gu H. H. (2003) Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter. Mol. Pharmacol. 63, 653-658.
42. Yamashita A., Singh S. K., Kawate T., Jin Y. and Gouaux E. (2005) Crystal structure of a bacterial homologue of Na+/Cl - dependent neurotransmitter transporters. Nature 437, 215-223.